Cancer/testis antigen 1 (89-100)

Cancer/testis antigen 1 (89-100) is a synthetic peptide fragment derived from the immunodominant region of the well-characterized cancer/testis antigen family. Recognized for its restricted expression in various malignancies and minimal presence in normal adult tissues, this peptide segment represents a valuable molecular tool for dissecting tumor-associated antigenicity and immune recognition. Its defined sequence and immunological relevance make it an important asset in studies focused on tumor immunology, antigen processing, and peptide-based assay development.

Immunological assay development: The 89-100 peptide fragment serves as a robust standard for the development and optimization of immunological assays, such as ELISpot, ELISA, or flow cytometry-based detection of antigen-specific T cell responses. Its defined epitope enables researchers to quantify and characterize cellular immune responses targeting cancer/testis antigens, providing critical insights into the immunogenicity of tumor-associated peptides and their potential for immune monitoring in preclinical research settings.

Epitope mapping and T cell specificity: Researchers utilize this peptide to map T cell epitopes and investigate the specificity of cytotoxic T lymphocyte (CTL) responses in the context of cancer immunology. By presenting the peptide on major histocompatibility complex (MHC) molecules, it is possible to determine the precise T cell receptor (TCR) recognition motifs and to analyze the breadth and affinity of T cell populations reactive to tumor-associated antigens. Such studies are instrumental in elucidating mechanisms of immune surveillance and escape in tumor environments.

Peptide-MHC binding studies: The Cancer/testis antigen 1 (89-100) peptide is frequently employed in binding assays to assess its interaction with various MHC class I alleles. Quantitative and qualitative analysis of peptide-MHC stability and affinity aids in understanding antigen presentation dynamics and supports the rational design of antigenic peptides for immunological research. These studies contribute to the selection of optimal candidate sequences for further exploration in antigen processing and presentation models.

Synthetic peptide validation and quality control: As a reference standard, this peptide fragment is used to validate synthetic peptide production processes and to calibrate analytical instrumentation in peptide chemistry laboratories. Its inclusion in method development protocols ensures reproducibility and accuracy in peptide synthesis, purification, and mass spectrometric analysis, thereby supporting high-confidence research outcomes in the field of peptide-based biochemistry.

Functional studies in antigen processing: The defined sequence and immunological relevance of Cancer/testis antigen 1 (89-100) make it suitable for probing antigen processing pathways in vitro. By incorporating the peptide into antigen-presenting cell systems, investigators can dissect the mechanisms of peptide uptake, processing, and presentation, facilitating a deeper understanding of cellular pathways that govern immune recognition of tumor antigens. These studies are fundamental for advancing knowledge in tumor immunobiology and for informing the design of innovative immunological research tools.

1. Myotropic activity and immunolocalization of selected neuropeptides of the burying beetle Nicrophorus vespilloides (Coleoptera: Silphidae)

2. Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma

3. cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging

4. Characterization of Novel P-Selectin Targeted Complement Inhibitors in Murine Models of Hindlimb Injury and Transplantation

5. Zeta-potential-changing nanoparticles conjugated with cell-penetrating peptides for enhanced transfection efficiency